Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03013218 · ClinicalTrials.gov registry record · Phase 1
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
A Phase 1 study of Solid Tumor and Advanced Cancer, sponsored by ALX Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 174
- Enrollment target
- 10
- Study locations
NCT03013218: Completed Phase 1 study of Solid Tumor and Advanced Cancer, sponsored by ALX Oncology.
NCT03013218 is a Phase 1 study of Solid Tumor and Advanced Cancer that has completed, run by ALX Oncology. The registered enrollment target is 174 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (21% lower). The trial reports 10 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03013218, a Phase 1 study of Solid Tumor and Advanced Cancer, has completed, sponsored by ALX Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 174 participants
- Enrollment target
- 10
- Study locations
Study Summary
A phase 1, dose escalation study of evorpacept (ALX148) in patients with advanced solid tumors and lymphoma
Primary Outcome
Number of participants with a DLT
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Trastuzumab
- DRUG Rituximab
- DRUG Evorpacept (ALX148)
- DRUG Ramucirumab + Paclitaxel
Study Locations (10)
Other
- Seoul National University Bundang Hospital - Seongnam
- Samsung Medical Center - Seoul
- Seoul National University Hospital - Seoul
- Severance Hospital, Yonsei University - Seoul
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Colorado
- University of Colorado Denver - Denver
Connecticut
- Yale University - New Haven
Michigan
- START-Midwest - Grand Rapids
Washington
- Seattle Cancer Care Alliance - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2017-02-03 |
| Est. Completion | 2025-07-08 |
| Phase | Phase 1 |
What the finished NCT03013218 record still lists
NCT03013218 is an interventional study that assigns participants to a tested intervention. The registered 174 participants enrollment target is mid-sized for trials with a published cap, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (21% lower).
The record links to 4 conditions, with Solid Tumor appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT03013218 lists 10 locations in 6 states (Other, Massachusetts, Colorado).
Frequently Asked Questions
What is clinical trial NCT03013218 about?
NCT03013218 is a clinical study titled "A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)". A phase 1, dose escalation study of evorpacept (ALX148) in patients with advanced solid tumors and lymphoma
What is the current status of trial NCT03013218?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 174 participants. The study started on 2017-02-03. Estimated completion is 2025-07-08.
What conditions does trial NCT03013218 study?
This clinical trial studies the following conditions: Solid Tumor, Advanced Cancer, Metastatic Cancer, Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT03013218?
The interventions under investigation include: Pembrolizumab (DRUG), Trastuzumab (DRUG), Rituximab (DRUG), Evorpacept (ALX148) (DRUG), Ramucirumab + Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT03013218?
This trial is sponsored by ALX Oncology, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03013218 being conducted?
This trial has 10 study locations across Colorado, Connecticut, Massachusetts, Michigan, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03013218's enrollment target sits among peer trials
174 50th of 196 higher than 147 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01000259 · 174 participants
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
- NCT04729114 · 174 participants · Phase 1
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
- NCT04884035 · 174 participants · Phase 1
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
- NCT05075980 · 174 participants · Phase 2
Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI